Are Anti-Beta ETFs Like BTAL Worth Owning In 2026?

Photo of Austin Smith
By Austin Smith Published

Quick Read

  • BTAL gained 19% in 2022 when the S&P 500 fell 18%.

  • The fund lost 22.8% in 2025 while the S&P 500 gained 17.2%.

  • Over the past decade BTAL declined 23% while the S&P 500 surged 241%.

  • Are you ahead, or behind on retirement? SmartAsset's free tool can match you with a financial advisor in minutes to help you answer that today. Each advisor has been carefully vetted, and must act in your best interests. Don't waste another minute; learn more here.(Sponsor)

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Are Anti-Beta ETFs Like BTAL Worth Owning In 2026?

© monsitj / iStock via Getty Images

When high-beta stocks stumble and markets turn volatile, AGFiQ U.S. Market Neutral Anti-Beta Fund (NYSEARCA:BTAL) is designed to deliver. The fund goes long low-beta stocks and short high-beta stocks, betting that defensive names will outperform momentum favorites when risk appetite fades. It’s portfolio insurance with a 1.40% price tag.

An infographic titled 'BTAL: The Anti-Beta Hedge ETF' explaining its mechanics, use cases, pros, and cons. Section 1, 'HOW IT WORKS,' illustrates the strategy: 'LONG: Low-Beta Stocks (Defensive)' with an upward trend chart, connected by an arrow to 'SHORT: High-Beta Stocks (Momentum)' with a downward trend chart, leading to 'Result: Profits from Market Volatility & Fear.' Section 2, 'BEST USE CASE,' identifies 'Sustained Market Corrections' under 'Rising Volatility & Bear Markets,' listing 'Sustained market corrections (>10% drawdowns)' and 'High-beta stock selloffs,' with a note: 'Proven Hedge: Gained +19% in 2022 (when S&P 500 fell -18%).' Section 3, 'PROS & CONS,' presents two columns. 'Pros' include 'Portfolio Insurance (During broad market stress)' and 'Highly Diversified: No single stock >0.10% weight.' 'Cons' include 'Significant Bull Market Drag,' '2025 Performance: BTAL -22.78% vs S&P +17.22% (YTD),' 'Long-Term Underperformance (10-Year: -23.12% vs S&P +240.64%),' and 'High Cost: 1.40% Expense Ratio.' The infographic concludes with 'Key Challenge: Timing is critical. A tactical tool, not a buy-and-hold investment.'
24/7 Wall St.
This infographic details the BTAL Anti-Beta Hedge ETF’s strategy of going long low-beta and short high-beta stocks, outlining its best use cases in volatile markets, and presenting its pros and cons.

The problem? 2025 was the opposite of a defensive year. BTAL lost 22.8% while the S&P 500 gained 17.2%, a 40-percentage-point gap that highlights the fund’s core limitation: it only works when markets cooperate. Over the past decade, BTAL has declined 23% while the S&P 500 has surged 241%. That’s a 264-percentage-point opportunity cost for holding what amounts to permanent portfolio drag during bull markets.

 
 

When BTAL Actually Works

The fund isn’t broken. It gained 19% in 2022 when the S&P 500 fell 18%, proving the strategy can deliver during broad market stress. The anti-beta approach provides genuine diversification when traditional equity hedges fail, but timing when to hold it remains the challenge for most investors. 

The question about whether BTAL makes sense to own in 2026 depends on your view of what markets will do. the S&P 500 has had three years of back-to-back-back positive returns. And the gains have all been meaningfully positive with double digit returns. Vanguard’s 2026 investment outlook forecasts mid single digit returns for the year, while also expecting elevated valuations. That’s a bit of a knife’s edge to walk, continuing to see appreciation with stretched multiples. 

Blackrock is also calling for US equities to outperform peers again in 2026, while JP Morgan sees slower growth but no recession. If you align with these reports, BTAL is likely dead money in 2026. But if you think there is a reasonable (say, 20% chance or greater) that the S&P 500 puts up a down year and volatility rips back, then BTAL is a worthy insurance policy in your portfolio. 

For my money, I say even after a poor performance the last few years, the AGFiQ U.S. Market Neutral Anti-Beta Fund is worth holding on to. 

Photo of Austin Smith
About the Author Austin Smith →

Austin Smith is a financial publisher with over two decades of experience in the markets. He spent over a decade at The Motley Fool as a senior editor for Fool.com, portfolio advisor for Millionacres, and launched new brands in the personal finance and real estate investing space.

His work has been featured on Fool.com, NPR, CNBC, USA Today, Yahoo Finance, MSN, AOL, Marketwatch, and many other publications. Today he writes for 24/7 Wall St and covers equities, REITs, and ETFs for readers. He is as an advisor to private companies, and co-hosts The AI Investor Podcast.

When not looking for investment opportunities, he can be found skiing, running, or playing soccer with his children. Learn more about me here.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

SBAC Vol: 4,127,800
+$24.30
+14.16%
$195.86
CCI Vol: 3,935,378
+$4.72
+5.84%
$85.55
INTC Vol: 96,496,008
+$2.03
+4.22%
$50.06
LYB Vol: 5,334,148
+$3.08
+4.01%
$79.79
GLW Vol: 8,343,716
+$5.19
+3.65%
$147.57

Top Losing Stocks

ENPH Vol: 4,188,820
-$2.89
7.55%
$35.39
TSLA Vol: 65,727,072
-$21.85
5.73%
$359.41
CCL Vol: 20,376,455
-$1.07
4.01%
$25.52
BMY Vol: 8,243,596
-$2.37
3.84%
$59.36
BIIB Vol: 871,373
-$6.82
3.71%
$176.97